Evidence map›Paper›PMID 40503427›Full record

ArticleAdvances in radiation oncology2025

Sequential

Daniel F Polan, Justin K Mikell, Kellen Fitzpatrick, Joseph J Gemmete, Jared A Christensen, Hassan Anbari, Molly Roseland, Joseph R Evans, Daniel T Chang, Mamadou Sanogo and 7 more

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advances in radiation oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04518748 (A Phase 1 Study of Combined Y-90 Selective Internal Radiation Therapy), which is not on this map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04518748 phase1active not recruitingnot on this map

A Phase 1 Study of Combined Y-90 Selective Internal Radiation Therapy (Y-90 SIRT) and Stereotactic Body Radiation Therapy (SBRT) in Hepatic Malignancy.

TypeinterventionalSponsorUniversity of Michigan Rogel Cancer CenterRan2020 to 2028Enrolled70ConditionsLiver MalignancyArmsYttrium-90, Selective Internal Radiation Therapy, Stereotactic Body Radiation Therapy, PET/CT, Therasphere
3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Dosimetry-Driven Personalization of Radiopharmaceutical Therapies: Evidence and Opportunities.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026
    Review
  2. Review
  3. Evaluation of end-to-end 3D absorbed dose distribution inEuropean journal of nuclear medicine and molecular imaging · 2026
    Article
  4. CT-free attenuation and Monte-Carlo based scatter correction-guided quantitativeEuropean journal of nuclear medicine and molecular imaging · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Daniel F PolanDepartment of Radiation Oncology, University of Michigan, Ann Arbor, Michigan.
Justin K MikellDepartment of Radiation Oncology, Washington University in St. Louis, St. Louis, Missouri.
Kellen FitzpatrickDepartment of Radiology, University of Michigan, Ann Arbor, Michigan.
Joseph J GemmeteDepartment of Radiology, University of Michigan, Ann Arbor, Michigan.
Jared A ChristensenDepartment of Radiology, University of Michigan, Ann Arbor, Michigan.
Hassan AnbariDepartment of Radiology, University of Michigan, Ann Arbor, Michigan.
Molly RoselandDepartment of Radiology, University of Michigan, Ann Arbor, Michigan.
Joseph R EvansDepartment of Radiation Oncology, University of Michigan, Ann Arbor, Michigan.
Daniel T ChangDepartment of Radiation Oncology, University of Michigan, Ann Arbor, Michigan.
Mamadou SanogoDepartment of Radiology, University of Michigan, Ann Arbor, Michigan.
Baljendra S KapoorDepartment of Radiology, University of Michigan, Ann Arbor, Michigan.
Matthew J SchipperDepartment of Radiation Oncology, University of Michigan, Ann Arbor, Michigan.
Yue CaoDepartment of Radiation Oncology, University of Michigan, Ann Arbor, Michigan.
Madhava P AryalDepartment of Radiation Oncology, University of Michigan, Ann Arbor, Michigan.
Theodore S LawrenceDepartment of Radiation Oncology, University of Michigan, Ann Arbor, Michigan.
Kyle C CuneoDepartment of Radiation Oncology, University of Michigan, Ann Arbor, Michigan.
Yuni K DewarajaDepartment of Radiology, University of Michigan, Ann Arbor, Michigan.

Funding

XenograftP30CA046592 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Alexey I Nesvizhskii · 1988 to 2026
$178.2M
Imaging and Dosimetry of Yttrium-90 for Personalized Cancer TreatmentR01EB022075 · NIBIB · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI DEWARAJA, YUNI K · 2016 to 2023
$4.7M
NCI NIH HHS P30 CA046592NIBIB NIH HHS R01 EB022075
6 · The paper itself

Abstract

Purpose: Selective internal radiation therapy (SIRT) can result in heterogeneous absorbed dose coverage. To address potential underdosing of lesions with SIRT, we designed a phase 1 clinical trial (NCT04518748) to add stereotactic body radiation therapy (SBRT) 6 weeks after Methods and Materials: In this ongoing, single-center prospective trial, patients received standard-of-care Results: Of the 24 patients who received SIRT as part of the trial, 15 had lesions that were considered dosimetrically eligible for SBRT based on the criteria of 290 Gy mean absorbed dose from Conclusions: Interim analysis found that liver toxicity from

Identifiers

PMID40503427
PMCPMC12152540

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.